lymph node cancer

Lymph node cancer or lymphomas (flash) is a type of cancer that grows by mutations lymphocyte cells (a type of white blood cells) previously normal. This resulted in abnormal nenjadi malignant cells. Like normal lymphocytes, malignant lymphocytes can grow in various Organs in the body including lymph nodes, spleen, sum-sum bones, blood or other Organs.

There are two kinds of lymphatic system cancers: Hodgkin's disease and Non-Hodgkin's lymphoma (NHL) (flash). NHL is a group of diseases related malignancy that Affects the lymphatic system.

Lymphatic System

The lymphatic system is an important part of the immune system plays a key role in the body's natural defenses against infection and cancer. The lymphatic fluid is a white liquid like milk protein, fat, and lymphocytes (white blood cells) that all flow throughout the body via the lymphatic vessels. There are two kinds of cells are lymphocytes: B cells and T cells

B cells help protect the body against bacteria by making antibodies that attack and destroy bacteria.

Symptoms and signs

NHL signs and symptoms include swollen lymph nodes (in the neck, armpit or groin). Gland enlargement was able to start with symptoms of weight loss, fever, night sweats. There is no early detection test for the NHL. If the above symptoms are found, it is advisable to go to the doctor for further examination.

Causes NHL

The exact cause is unknown. Four possible causes are: genetics, immune system disorders, viral or bacterial infections (HIV, HCV, EBV, Helicobacter Sp) and environmental toxins (herbicides, preservatives and chemical dyes).

Types of NHL

There are more than 30 sub-types of NHL are different (90 percent of type B cells), which can be grouped according to some classification guidelines. Classification is to consider several factors like appearance under a microscope, the size, speed of growth and organ affected.
Generally recognized some form of NHL that is very aggressive (fast growing), intermediate and indolent (slow growing). The determination was carried out with a microscope by a pathologist in the laboratory.

Medical

NHL cores currently treatments include chemotherapy, monoclonal antibody therapy, radiation, biological therapy and Transplantation of bone-sum-sum. Determining which type of therapy depends taken very individual condition of patients and depends on 3 main factors:

1. Stadium
2. Size
3. Degree of malignancy

Lymphoma Aggressive (intermediate / high degree of malignancy) to grow and spread quickly in the body and if left without treatment can kill within 6 months. Life Expectancy ranges from an average of 5 years with about 30-40% Healed. Patients who are diagnosed early and treated immediately are more likely to achieve complete remission and rarely experienced a Relapse. Because there is potential for recovery, it is usually more aggressive treatment.

Standard therapy includes former standard CHOP chemotherapy and / or high-dose chemotherapy and Transplantation sum-sum. Recently, the use of rituximab plus standard chemotherapy has been recommended by European researchers who treat aggressive NHL based on a test that shows Clinicians extension of Life Expectancy of patients when treated with rituximab + CHOP compared to CHOP only.

Indolent lymphoma (low degree of malignancy) grow slowly so early diagnostics becomes more difficult. Patients can survive for years with this disease, but no standard treatment can not cure. Usually, patients respond well to initial therapy, but it is very possible the cancer grew back.

Patients with indolent lymphoma can get the therapy for five to six times throughout their lives. However, patients usually respond to lower the therapy. Life Expectancy in this type of lymphoma, where patients often defeated by the disease or complications that Arise, ranging between six months.

Linfoma developments in Indonesia is quite fast. Based on the number of patients seeking help at the RSCM and Dharmais Hospital Cancer Foundation, an average of 300 people each year. Whereas in 2005 only 150 people per year.

0 comments:

Post a Comment